Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality-A retrospective nationwide study

Diabetes Research and Clinical Practice

Volumn 107, Issue 1, 2015, Pages 104-112

  Mogensen, Ulrik Madvig ^a   Andersson, Charlotte ^b   Fosbøl, Emil Loldrup ^a   Schramm, Tina Ken ^c   Vaag, Allan ^a   Scheller, Nikolai Madrid ^f   Torp Pedersen, Christian ^f   Gislason, Gunnar ^b,d,e   Køber, Lars ^a  

^a University of Copenhagen   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c FREDERIKSBERG HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f AALBORG UNIVERSITY   (Denmark)

Author keywords

Cardiovascular risk; Combination therapy; Insulin secretagogues; Metformin; Sulfonylurea; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; METFORMIN; REPAGLINIDE; TOLBUTAMIDE; CARBAMATES; GLUCOVANCE; GLYBURIDE; HYPOGLYCEMIC AGENTS; PIPERIDINES; SULFONYLUREA COMPOUNDS;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; FEMALE; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; RISK ASSESSMENT; AGED; BLOOD; CARDIOVASCULAR DISEASES; DENMARK; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS AND NUMERICAL DATA; STROKE;

AGED; CARBAMATES; CARDIOVASCULAR DISEASES; DENMARK; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLICLAZIDE; GLIPIZIDE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; MORBIDITY; MYOCARDIAL INFARCTION; PIPERIDINES; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; SULFONYLUREA COMPOUNDS; TOLBUTAMIDE;

EID: 84922814154     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.09.047     Document Type: Article

References (40)

1. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
2. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65.
3. Rao A.D., Kuhadiya N., Reynolds K., Fonseca V.A. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies. Diabetes Care 2008, 31:1672-1678.
4. Lamanna C., Monami M., Marchionni N., Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2011, 13:221-228.
5. Boussageon R., Supper I., Bejan-Angoulvant T., Kellou N., Cucherat M., Boissel J.P., et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 2012, 9:e1001204.
6. Evans J.M., Ogston S.A., Reimann F., Gribble F.M., Morris A.D., Pearson E.R. No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis. Diabetes Obes Metab 2008, 10:350-352.
7. Pantalone K.M., Kattan M.W., Yu C., Wells B.J., Arrigain S., Jain A., et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 2010, 33:1224-1229.
8. Andersson C., Gislason G.H., Jorgensen C.H., Hansen P.R., Vaag A., Sorensen R., et al. Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. Diabetes Res Clin Pract 2011, 94:119-125.
9. Horsdal H.T., Johnsen S.P., Sondergaard F., Jacobsen J., Thomsen R.W., Schmitz O., et al. Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study. Diabetes Metab Res Rev 2009, 25:515-522.
10. Zeller M., Danchin N., Simon D., Vahanian A., Lorgis L., Cottin Y., et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 2010, 95:4993-5002.
11. Khalangot M., Tronko M., Kravchenko V., Kovtun V. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract 2009, 86:247-253.
12. Schramm T.K., Gislason G.H., Vaag A., Rasmussen J.N., Folke F., Hansen M.L., et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011, 32:1900-1908.
13. Holstein A., Plaschke A., Egberts E.H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001, 17:467-473.
14. Gangji A.S., Cukierman T., Gerstein H.C., Goldsmith C.H., Clase C.M. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007, 30:389-394.
15. O'Brien R.C., Luo M., Balazs N., Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications 2000, 14:201-206.
16. Abdelmoneim A.S., Hasenbank S.E., Seubert J.M., Brocks D.R., Light P.E., Simpson S.H. Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes Metab 2012, 14:130-138.
17. Kimoto K., Suzuki K., Kizaki T., Hitomi Y., Ishida H., Katsuta H., et al. Gliclazide protects pancreatic beta-cells from damage by hydrogen peroxide. Biochem Biophys Res Commun 2003, 303:112-119.
18. Fosbol E.L., Gislason G.H., Jacobsen S., Abildstrom S.Z., Hansen M.L., Schramm T.K., et al. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiol Drug Saf 2008, 17:822-833.
19. Olsen A.M., Fosbol E.L., Lindhardsen J., Andersson C., Folke F., Nielsen M.B., et al. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients-a nationwide study. PLoS One 2013, 8:e54309.
20. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
21. Wright A., Burden A.C., Paisey R.B., Cull C.A., Holman R.R. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002, 25:330-336.
22. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49), UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281:2005-2012.
23. Gore M.O., McGuire D.K. Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments. Eur Heart J 2011, 32:1832-1834.
24. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
25. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
26. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
27. Monami M., Luzzi C., Lamanna C., Chiasserini V., Addante F., Desideri C.M., et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006, 22:477-482.
28. Monami M., Marchionni N., Masotti G., Mannucci E. Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease. Int J Cardiol 2008, 126:247-251.
29. Pantalone K.M., Kattan M.W., Yu C., Wells B.J., Arrigain S., et al. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis. Diabet Med 2012, 29:1029-1035.
30. Gribble F.M., Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complications 2003, 17:11-15.
31. Tomai F., Crea F., Gaspardone A., Versaci F., De P.R., Penta de P.A., et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+channel blocker. Circulation 1994, 90:700-705.
32. Lee T.M., Chou T.F. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003, 88:531-537.
33. Klepzig H., Kober G., Matter C., Luus H., Schneider H., Boedeker K.H., et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999, 20:439-446.
34. Maddock H.L., Siedlecka S.M., Yellon D.M. Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther 2004, 18:113-119.
35. Mocanu M.M., Maddock H.L., Baxter G.F., Lawrence C.L., Standen N.B., Yellon D.M. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001, 103:3111-3116.
36. Flynn D.M., Smith A.H., Treadway J.L., Levy C.B., Soeller W.C., Boettner W.A., et al. The sulfonylurea glipizide does not inhibit ischemic preconditioning in anesthetized rabbits. Cardiovasc Drugs Ther 2005, 19:337-346.
37. Sadikot S.M., Mogensen C.E. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. Diabetes Res Clin Pract 2008, 82:391-395.
38. Jorgensen C.H., Gislason G.H., Andersson C., Ahlehoff O., Charlot M., Schramm T.K., et al. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention-a retrospective nationwide cohort study. Cardiovasc Diabetol 2010, 9:54.
39. Johnsen S.P., Monster T.B., Olsen M.L., Thisted H., McLaughlin J.K., Sorensen H.T., et al. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther 2006, 13:134-140.
40. Juurlink D.N., Gomes T., Shah B.R., Mamdani M.M. Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population. Diabet Med 2012, 29:1524-1528.